Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Blu-5937
2. Methyl (s)-3-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo(1,2-a)pyridin-3-yl)methyl)piperidine-1-carboxylate
1. Blu-5937
2. Tb7d2h7mzz
3. 1621164-74-6
4. (s)-methyl-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
5. 4-morpholinecarboxylic Acid, 2-((2-(2,6-difluoro-4-((methylamino)carbonyl)phenyl)-7-methylimidazo(1,2-a)pyridin-3-yl)methyl)-, Methyl Ester, (2s)-
6. Camlipixant [inn]
7. Unii-tb7d2h7mzz
8. Chembl5095035
9. Schembl15923275
10. A935056
11. Methyl (2s)-2-({2-[2,6-difluoro-4- (methylcarbamoyl)phenyl]-7-methylimidazo[1,2- A]pyridin-3-yl}methyl)morpholine-4-carboxylate
12. Methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)-phenyl)-7-methylimidazo(1,2-a)pyridin-3-yl)methyl)-morpholine-4-carboxylate
| Molecular Weight | 458.5 g/mol |
|---|---|
| Molecular Formula | C23H24F2N4O4 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 85.2 |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 704 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2023
Details:
The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: GSK
Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million
Deal Type: Acquisition June 28, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
GSK Completes Acquisition of BELLUS Health
Details : The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : $2,000.0 million
June 28, 2023
Details:
BLU-5937 (camlipixant) is an investigational P2X3 antagonist, for the treatment of refractory chronic cough. Clinical evidence have linked the P2X3 receptor and refractory chronic cough to a sensory nerve dysfunction that can lead to cough hypersensitivity.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 (camlipixant) is an investigational P2X3 antagonist, for the treatment of refractory chronic cough. Clinical evidence have linked the P2X3 receptor and refractory chronic cough to a sensory nerve dysfunction that can lead to cough hypersensitivi...
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2023
Details:
The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: GSK
Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million
Deal Type: Acquisition April 18, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company BELLUS Health
Details : The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : $2,000.0 million
April 18, 2023
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2022
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Details:
The company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the Supplement (as defined below).
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Jefferies
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 18, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $153.0 million
Deal Type : Public Offering
Details : The company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the Supplement (as defined below).
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2022
Details:
The Company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the supplement.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Jefferies
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 14, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $153.0 million
Deal Type : Public Offering
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
Details : The Company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the supplement.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 14, 2022
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics, for the treatment of refractory chronic cough.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics, for the treatment of refractory chronic cough.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2022
Details:
Phase 2b SOOTHE trial which highlight BLU-5937 was well-tolerated with a low rate of taste-related adverse events (?6.5%) treatment emergent adverse event profile comparable to placebo used for the treatment of refractory chronic cough.
Lead Product(s): Camlipixant
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLU-5937
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2021
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2b SOOTHE trial which highlight BLU-5937 was well-tolerated with a low rate of taste-related adverse events (?6.5%) treatment emergent adverse event profile comparable to placebo used for the treatment of refractory chronic cough.
Product Name : BLU-5937
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
CAS Number : 695-34-1
End Use API : Camlipixant
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
76
PharmaCompass offers a list of Camlipixant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Camlipixant manufacturer or Camlipixant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Camlipixant manufacturer or Camlipixant supplier.
PharmaCompass also assists you with knowing the Camlipixant API Price utilized in the formulation of products. Camlipixant API Price is not always fixed or binding as the Camlipixant Price is obtained through a variety of data sources. The Camlipixant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Camlipixant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Camlipixant, including repackagers and relabelers. The FDA regulates Camlipixant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Camlipixant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Camlipixant supplier is an individual or a company that provides Camlipixant active pharmaceutical ingredient (API) or Camlipixant finished formulations upon request. The Camlipixant suppliers may include Camlipixant API manufacturers, exporters, distributors and traders.
Camlipixant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Camlipixant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Camlipixant GMP manufacturer or Camlipixant GMP API supplier for your needs.
A Camlipixant CoA (Certificate of Analysis) is a formal document that attests to Camlipixant's compliance with Camlipixant specifications and serves as a tool for batch-level quality control.
Camlipixant CoA mostly includes findings from lab analyses of a specific batch. For each Camlipixant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Camlipixant may be tested according to a variety of international standards, such as European Pharmacopoeia (Camlipixant EP), Camlipixant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Camlipixant USP).
